JPWO2018051895A1 - 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 - Google Patents
乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 Download PDFInfo
- Publication number
- JPWO2018051895A1 JPWO2018051895A1 JP2018539671A JP2018539671A JPWO2018051895A1 JP WO2018051895 A1 JPWO2018051895 A1 JP WO2018051895A1 JP 2018539671 A JP2018539671 A JP 2018539671A JP 2018539671 A JP2018539671 A JP 2018539671A JP WO2018051895 A1 JPWO2018051895 A1 JP WO2018051895A1
- Authority
- JP
- Japan
- Prior art keywords
- skin
- bacteria
- lactic acid
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 105
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 239000004310 lactic acid Substances 0.000 title claims abstract description 50
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 25
- 230000006866 deterioration Effects 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 37
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 208000012868 Overgrowth Diseases 0.000 claims abstract description 12
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 42
- 230000001580 bacterial effect Effects 0.000 claims description 23
- 241000191967 Staphylococcus aureus Species 0.000 claims description 21
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 17
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 9
- 241000194017 Streptococcus Species 0.000 claims description 9
- 206010000496 acne Diseases 0.000 claims description 9
- 241000186427 Cutibacterium acnes Species 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 206010016936 Folliculitis Diseases 0.000 claims description 6
- 229940055019 propionibacterium acne Drugs 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- 201000000297 Erysipelas Diseases 0.000 claims description 3
- 206010021531 Impetigo Diseases 0.000 claims description 3
- 208000006311 Pyoderma Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000194035 Lactococcus lactis Species 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 abstract description 19
- 244000000010 microbial pathogen Species 0.000 abstract description 5
- 244000005714 skin microbiome Species 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 84
- 244000057717 Streptococcus lactis Species 0.000 description 41
- 238000012360 testing method Methods 0.000 description 19
- 230000000844 anti-bacterial effect Effects 0.000 description 18
- 244000052616 bacterial pathogen Species 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 206010040882 skin lesion Diseases 0.000 description 16
- 231100000444 skin lesion Toxicity 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000037406 food intake Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000003902 lesion Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 206010040872 skin infection Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 235000012631 food intake Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 208000022362 bacterial infectious disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 101710125314 Beta-defensin 1 Proteins 0.000 description 4
- 101710125296 Beta-defensin 3 Proteins 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 3
- 101710177037 Beta-defensin 14 Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000019028 Epidermal thickening Diseases 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000019985 fermented beverage Nutrition 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229960004184 ketamine hydrochloride Drugs 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102100037437 Beta-defensin 1 Human genes 0.000 description 2
- 102100026887 Beta-defensin 103 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 101150060340 S100a8 gene Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 2
- 241000750300 Staphylococcus aureus MW2 Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100039803 Beta-defensin 114 Human genes 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000012180 bread and bread product Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- -1 sorbit etc. Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1] 乳酸菌を有効成分として含む、経口摂取により、細菌の異常増殖を抑制し、又は細菌の異常増殖に起因する皮膚状態の悪化を防止又は改善するための組成物。
[2] 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、A群β溶血性連鎖球菌(化膿レンサ球菌)(Streptococcus pyogenes)、緑膿菌(Pseudomonas aeruginosa)、蛍光発色性ジフテロイド(蛍光ジフテロイド)及びアクネ桿菌(Propionibacterium acnes)からなる群から選択される[1]の組成物。
[3] 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、アクネ桿菌(Propionibacterium acnes)からなる群から選択される、[2]の組成物。
[4] 前記乳酸菌が、ラクトコッカス属に属するものである、[1]〜[3]のいずれかの組成物。
[5] 前記乳酸菌が、ラクトコッカス・ラクティスである、[1]〜[3]のいずれかの組成物。
[6] 前記乳酸菌が、ラクトコッカス・ラクティスJCM5805株である、[1]〜[3]のいずれかの組成物。
[7] 食品組成物である、[1]〜[6]のいずれかの組成物。
[8] 医薬組成物である、[1]〜[6]のいずれかの組成物。
[9] 細菌の異常増殖に起因する皮膚の状態が肌荒れ、皮膚炎である、[7]又は[8]の組成物。
[10] 細菌の異常増殖に起因する皮膚の状態がとびひ(伝染性膿痂疹)、蜂窩織炎、丹毒、ブドウ球菌性熱傷様皮膚症候群、毛包炎、にきび、せつ、癰、細菌性爪囲塩、慢性膿皮症及び尋常性毛瘡からなる群から選択される[8]の組成物。
○ とびひ(伝染性膿痂疹)
水泡型 黄色ブドウ球菌
痂皮型 A群β溶血性連鎖球菌
○ 蜂窩織炎
ブドウ球菌、又はA群β溶血性連鎖球菌
○ 丹毒
A群β溶血性連鎖球菌
○ ブドウ球菌性熱傷様皮膚症候群(SSSS:Staphylococcal Scalded Skin Syndrome)
黄色ブドウ球菌
○ 毛包炎(毛嚢炎)
黄色ブドウ球菌及び表皮ブドウ球菌
○ にきび(尋常性ざ瘡)
ニキビは毛包炎の1種であり、青少年の顔面に生じる。
○ せつ(おでき)及び癰(よう)
せつ及び癰(よう)は毛包炎が進行したものをいう。
○ 細菌性爪囲塩
黄色ブドウ球菌、A群β溶血性レンサ球菌及び緑膿菌
○ 多発性汗腺膿瘍(ブドウ球菌性汗孔周囲炎)
黄色ブドウ球菌
○ 慢性膿皮症
黄色ブドウ球菌及び表皮ブドウ球菌
○ 尋常性毛瘡(かみそり負け)
黄色ブドウ球菌及び表皮ブドウ球菌
○ 紅色陰癬
蛍光ジフテロイド
また、アトピー性皮膚炎も黄色ブドウ球菌による感染が症状を悪化させることが報告されており、本発明の組成物はアトピー性皮膚炎の症状の緩和及び改善に用いることもできる。
本発明に使用した黄色ブドウ球菌は以下に示すような方法で調製した。
<実験方法>
Staphylococcus aureus MX2株を米国の生物資源バンクであるAmerican Type Culture Collection(ATCC)より入手した。試験の都度、試験管に普通ブイヨン培地(栄研社製)を10 mL入れ、凍結菌液を融解し、100 μLを接種した後、恒温振盪培養機(タイテック社製)で37℃、振盪培養した。培養後の菌懸濁液を遠心機にて遠心分離(1000 rpm、5分)し、上清を取り除いた。沈殿している菌に生理食塩液2 mLを加え攪拌し、接種菌原液とした。
<結果>
実施例2に使用した黄色ブドウ球菌濃度は3.4 x 106cfu/mL、実施例3に使用した黄色ブドウ球菌濃度は3.0 x 106 cfu/mLであった。
Lactococcus lactis JCM5805を経口摂取させたマウスの皮膚に黄色ブドウ球菌を接種し、病変度評価、黄色ブドウ球菌の生菌数測定、病理組織学的検査、抗細菌性遺伝子発現を実施し、細菌感染に対する防御効果を評価した。
<実験方法>
BALB/Cマウス(日本エスエルシー社より購入。5週齢メス)1群16匹ずつに分け、標準食摂取群(AIN-93G食・オリエンタル酵母工業社製)とLactococcus lactis JCM5805混餌投与群(Lactococcus lactis JCM5805摂取群)の2群を設定した。乳酸菌の投与量は1日1匹あたり1 mgに設定した。乳酸菌の投与開始時を0日として、14日目に塩酸ケタミン麻酔(筋肉内投与,2.0 mL / kg 、塩酸ケタミン注射液;動物用ケタラール(登録商標)50注射液;バイエル薬品株式会社)下でマウスの背部を電気カミソリで剃毛後、除毛クリーム(epilat(登録商標)、クラシエホームプロダクツ株式会社)を剃毛部位に塗り、約2 cm四方の被験部位を設定した。被験部位を布粘着テープで3回ストリッピングした。投与15日目に塩酸ケタミン麻酔下で、再度被験部位を布粘着テープで3回ストリッピングした後、マイクロピペットを用いて被験部位へ黄色ブドウ球菌の接種菌液を個体あたり0.1 mL (3.4×105 cfu/head)滴下した。
<結果>
図1に示すように、Lactococcus lactis JCM5805摂取群は標準食摂取群に比して、黄色ブドウ球菌の皮膚感染に起因する皮膚病変度が有意に低値を示すことが判明した。すなわち、Lactococcus lactis JCM5805には黄色ブドウ球菌皮膚感染による皮膚病変の重症化に対する軽減作用があることが示された。
実施例2で示したLactococcus lactis JCM5805を経口摂取させたマウスの皮膚に黄色ブドウ球菌を接種し、感染に起因する皮膚病変度を経時的に測定することにより、細菌感染に対する防御効果を病変が寛解するまでの期間評価した。
<実験方法>
BALB/Cマウス(日本エスエルシー社より購入。5週齢メス)1群3匹ずつに分け、標準食摂取群(AIN-93G食)とLactococcus lactis JCM5805混餌投与群(Lactococcus lactis JCM5805摂取群)の2群を設定した。乳酸菌の投与量、投与方法、黄色ブドウ球菌の接種は実施例2と同様の方法で行い、黄色ブドウ球菌接種0日目から6日目まで皮膚の病変度を評価した。
<結果>
図4に黄色ブドウ球菌感染後の皮膚病変評点を示した。Lactococcus lactis JCM5805摂取群はコントロール群に比して、すべての時点で病変評点が低値を示すことが判明した。
Lactococcus lactis JCM5805摂取時の皮膚の黄色ブドウ球菌に対する抗菌作用
Lactococcus lactis JCM5805を経口摂取させたマウスの皮膚の抽出液を用い、黄色ブドウ球菌に対する抗菌作用を、標準食を摂取したマウスと比較した。
<実験方法>
BALB/Cマウス(日本チャールズリバー社より購入。7週齢メス)1群8匹ずつに分け、標準食摂取群(AIN-93G食)とLactococcus lactis JCM 5805混餌投与群(Lactococcus lactis JCM5805摂取群)の2群を設定した。乳酸菌の投与量は1日1匹あたり1 mgに設定した。乳酸菌の投与開始時を0日として、14日目に解剖し、背面皮膚を採取した。
<結果>
図5に示すように、Lactococcus lactis JCM5805摂取群は標準食摂取群に比して、Staphylococcus aureus MW2株に対して、菌数が顕著に少なくなっており、抗菌性が高まっていることが示された。
Claims (10)
- 乳酸菌を有効成分として含む、経口摂取により、細菌の異常増殖を抑制し、又は細菌の異常増殖に起因する皮膚状態の悪化を防止又は改善するための組成物。
- 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、A群β溶血性連鎖球菌(化膿レンサ球菌)(Streptococcus pyogenes)、緑膿菌(Pseudomonas aeruginosa)、蛍光発色性ジフテロイド(蛍光ジフテロイド)及びアクネ桿菌(Propionibacterium acnes)からなる群から選択される請求項1記載の組成物。
- 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、アクネ桿菌(Propionibacterium acnes)からなる群から選択される、請求項2記載の組成物。
- 前記乳酸菌が、ラクトコッカス属に属するものである、請求項1〜3のいずれか1項に記載の組成物。
- 前記乳酸菌が、ラクトコッカス・ラクティスである、請求項1〜3のいずれか1項に記載の組成物。
- 前記乳酸菌が、ラクトコッカス・ラクティスJCM5805株である、請求項1〜3のいずれか1項に記載の組成物。
- 食品組成物である、請求項1〜6のいずれか1項に記載の組成物。
- 医薬組成物である、請求項1〜6のいずれか1項に記載の組成物。
- 細菌の異常増殖に起因する皮膚の状態が肌荒れ、皮膚炎である、請求項7又は8に記載の組成物。
- 細菌の異常増殖に起因する皮膚の状態がとびひ(伝染性膿痂疹)、蜂窩織炎、丹毒、ブドウ球菌性熱傷様皮膚症候群、毛包炎、にきび、せつ、癰、細菌性爪囲塩、慢性膿皮症及び尋常性毛瘡からなる群から選択される請求項8記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016180851 | 2016-09-15 | ||
JP2016180851 | 2016-09-15 | ||
PCT/JP2017/032330 WO2018051895A1 (ja) | 2016-09-15 | 2017-09-07 | 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2018051895A1 true JPWO2018051895A1 (ja) | 2019-06-24 |
JP6652648B2 JP6652648B2 (ja) | 2020-02-26 |
Family
ID=61619454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018539671A Active JP6652648B2 (ja) | 2016-09-15 | 2017-09-07 | 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11382939B2 (ja) |
EP (1) | EP3513799A4 (ja) |
JP (1) | JP6652648B2 (ja) |
CA (1) | CA3036937C (ja) |
MY (1) | MY196871A (ja) |
WO (1) | WO2018051895A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6846376B2 (ja) | 2018-03-15 | 2021-03-24 | キリンホールディングス株式会社 | 皮膚状態改善用組成物 |
JP7045671B2 (ja) * | 2018-11-12 | 2022-04-01 | 有限会社バイオ研 | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002171933A (ja) | 2000-12-07 | 2002-06-18 | Ko Gijutsu Kenkyusho:Kk | キムチエキス健康食品 |
KR100467068B1 (ko) | 2002-03-06 | 2005-01-24 | 정명준 | 락토코쿠스 락티스 씨비티-19, 이를 이용한 항균 배양액분리 농축물의 제조 방법 및 이를 포함하는 화장료 조성물 |
IE20030773A1 (en) | 2003-10-17 | 2005-04-20 | Teagasc Agric Food Dev Authori | Use of probiotic bacteria in the treatment of infection |
GB0410785D0 (en) | 2004-05-14 | 2004-06-16 | Glycologic Ltd | Improved prebiotic |
KR100479719B1 (ko) * | 2005-01-29 | 2005-03-31 | 주식회사 프로바이오닉 | 유해 병원성 미생물 생육 억제능 및 항알레르기성을 갖는 신규 내산성 락토바실러스 사케이 Probio-65 |
EP1736537A1 (en) | 2005-06-22 | 2006-12-27 | OrganoBalance GmbH | Methods and means for protecting the skin against pathogenic microorganisms |
FR2938437B1 (fr) | 2008-11-19 | 2020-03-27 | Société des Produits Nestlé S.A. | Utilisation cosmetique de microorganisme pour le traitement des peaux grasses |
RU2562097C2 (ru) * | 2009-05-13 | 2015-09-10 | Конинклейке Филипс Электроникс Н.В. | Резкий переход в круговом световодном кольце для пользовательского интерфейса с функциональными возможностями с определенным началом и концом |
WO2012152270A1 (de) | 2011-05-06 | 2012-11-15 | Organobalance Medical Ag | Neue milchsäurebakterien und diese enthaltende zusammensetzungen |
KR101918792B1 (ko) | 2011-05-16 | 2018-11-14 | 오르가노발란스 메디컬 아게 | 박테리아성 감기에 대한 신규 락트산 박테리아 및 그를 함유하는 조성물 |
GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
FR2999601B1 (fr) * | 2012-12-17 | 2015-01-30 | Urgo Lab | Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis |
WO2015182735A1 (ja) * | 2014-05-30 | 2015-12-03 | キリン株式会社 | 乳酸菌免疫賦活作用増強組成物及び乳酸菌免疫賦活作用増強方法 |
KR101618330B1 (ko) * | 2015-03-27 | 2016-05-09 | 중앙대학교 산학협력단 | 락토코커스 중앙젠시스를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
ITUB20153106A1 (it) | 2015-08-13 | 2017-02-13 | Probiotical Spa | Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne |
JP6846376B2 (ja) * | 2018-03-15 | 2021-03-24 | キリンホールディングス株式会社 | 皮膚状態改善用組成物 |
-
2017
- 2017-09-07 EP EP17850798.4A patent/EP3513799A4/en active Pending
- 2017-09-07 CA CA3036937A patent/CA3036937C/en active Active
- 2017-09-07 JP JP2018539671A patent/JP6652648B2/ja active Active
- 2017-09-07 US US16/333,548 patent/US11382939B2/en active Active
- 2017-09-07 MY MYPI2019001274A patent/MY196871A/en unknown
- 2017-09-07 WO PCT/JP2017/032330 patent/WO2018051895A1/ja unknown
Also Published As
Publication number | Publication date |
---|---|
EP3513799A1 (en) | 2019-07-24 |
WO2018051895A1 (ja) | 2018-03-22 |
CA3036937C (en) | 2023-01-17 |
EP3513799A4 (en) | 2020-04-29 |
US20200179463A1 (en) | 2020-06-11 |
JP6652648B2 (ja) | 2020-02-26 |
CA3036937A1 (en) | 2018-03-22 |
US11382939B2 (en) | 2022-07-12 |
MY196871A (en) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohammad et al. | Probiotic properties of bacteria isolated from bee bread of stingless bee Heterotrigona itama | |
CN102970997B (zh) | 抗肥胖剂、抗肥胖用饮食品、糖耐量改善剂和糖耐量改善用饮食品 | |
US20200405789A1 (en) | Lactobacillus sp. strain having ability to inhibit growth of virginal pathogenic microorganisms | |
Saber et al. | Secretion metabolites of dairy Kluyveromyces marxianus AS41 isolated as probiotic, induces apoptosis in different human cancer cell lines and exhibit anti-pathogenic effects | |
JP6839329B2 (ja) | ヘリコバクター・ピロリ感染症の管理のための組成物 | |
TW201043151A (en) | Agent for preventing or improving obesity | |
TW201130496A (en) | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application | |
KR102434487B1 (ko) | 질염 원인균에 대한 항균 활성을 갖는 질 유래 락토바실러스 람노서스 vg.q2 균주 및 이의 용도 | |
KR20130048946A (ko) | 락토바실러스 루테리 cs132 또는 이의 배양물을 포함하는 항암용 조성물 | |
JP6652648B2 (ja) | 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 | |
EP3432900A1 (en) | Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections | |
JP2013116089A (ja) | 抗ヘリコバクター・ピロリ効果を有する乳酸菌株、その乳酸菌株を含む抗ヘリコバクター・ピロリ剤、及びその乳酸菌株を含む飲食品 | |
WO2017163216A1 (en) | Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections | |
KR100954882B1 (ko) | 조류 인플루엔자 바이러스 감염억제 효과를 가지는 신규 유산균 및 이를 포함하는 조성물 | |
KR101795115B1 (ko) | 감마-리놀렌산을 포함하는 결핵의 치료 및 예방용 항결핵 조성물 | |
JP2012180288A (ja) | 抗菌剤 | |
KR20220079092A (ko) | 신규 균주를 포함하는 염증성 질환 예방 또는 치료용 조성물 | |
Ajah | In vitro and in vivo studies on the antifungal activity of probiotics and seaweed extract (Ascophyllum nodosum) | |
JP3272023B2 (ja) | 白血球減少治療剤 | |
JP2019131475A (ja) | がん転移抑制剤 | |
JPH08283166A (ja) | 感染防御剤 | |
KR102208837B1 (ko) | 메틸 갈레이트 및 플로로퀴놀론 계열 항균제를 포함하는 박테리아의 장 부착, 침입 억제, 또는 항생제 내성 억제용 조성물 | |
US20240165173A1 (en) | Method of reducing uric acid by using lactobacillus paracasei lt12 | |
KR20220164351A (ko) | 케피어 유래 유산균의 배양물, 및 이를 포함하는 항균 조성물 및 기능성 식품 | |
JP2015151385A (ja) | 経口感染症の予防治療剤、及び該予防治療剤を含有する医薬品、機能性食品または飲食品添加物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190620 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190620 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190620 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190723 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200123 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6652648 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |